Product Description
Monovisc™, a single-injection intra-articular HA device, is a safe and effective treatment for providing a clinically meaningful reduction in knee pain within 2 weeks. The results of this study support the use of a single injection of hyaluronic acid (Monovisc™) for patients with symptomatic knee OA in patients older than 45 years, as a safe and effective alternative for patients who may want an alternative treatment modality or may not be candidates for partial or total knee replacement. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30159738/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Device
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Colombia | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Anika
Company Location: BEDFORD MA 01730
Company CEO: Cheryl Blanchard
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Osteoarthritis, Knee
Phase 3: Osteoarthritis, Hip
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EQE9-18-01 | N/A |
Completed |
Osteoarthritis, Knee |
2024-03-15 |
|
| 2022H0168 | P4 |
Terminated |
Osteoarthritis, Knee |
2023-01-11 |
|
| MON 18-03 | N/A |
Completed |
Osteoarthritis |
2021-02-26 |
|
| MON 18-02 | N/A |
Completed |
Osteoarthritis |
2021-02-26 |